4-ethyl-2H-1,2,3-Triazole → 2,6-Dichloro-9-[(1R,4S)-4-(4-ethyl-[1,2,3]triazol-2-yl)-cyclopent-2-enyl]-9H-purine
Reaction equation
C([N:8](C(OC(C)(C)C)=O)[C@H:9]1[CH2:13][C@@H:12]([N:14]2[CH:22]=[N:21][C:20]3[C:15]2=[N:16][C:17]([Cl:24])=[N:18][C:19]=3[Cl:23])[CH:11]=[CH:10]1)(OC(C)(C)C)=O.[CH2:32]([C:34]1[CH:38]=[N:37]N[N:35]=1)[CH3:33]>>[Cl:24][C:17]1[N:16]=[C:15]2[C:20]([N:21]=[CH:22][N:14]2[C@@H:12]2[CH2:13][C@H:9]([N:8]3[N:35]=[C:34]([CH2:32][CH3:33])[CH:38]=[N:37]3)[CH:10]=[CH:11]2)=[C:19]([Cl:23])[N:18]=1Participants
3
Procedure
The title compound is prepared analogously to di-Boc-[(1S,4R)-4-(2,6-dichloro-purin-9-yl)-cyclopent-2-enyl]-amine (AA3) by replacing di-t-butyliminodicarboxylate with 4-ethyl-2H-[1,2,3]triazole.
Sources & evidence
- ORD record
- ord-0b760b82ebc14b5a9ee3731e5eab03fb
- Source dataset
- uspto-grants-2012_06
- Patent number
- US08193164B2
Reaction notes
Loading…